Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Michael Levy, MD, PhD

Johns Hopkins University

Enrollment

38 target

Eligibility

18-100 years · All sexes

Timeline

2012 – 2018

Study locations (1)

• Johns Hopkins University, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Superficial siderosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07098650
  Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System
  Perspectum

See all trials for Superficial siderosis →